Carcinoma, Renal CellPhase 1NCT01672775
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
A Phase 1 study testing AGS-16C3F in people with Carcinoma, Renal Cell and Renal Cell Carcinoma of Papillary Histology, run by Agensys, Inc. at 9 sites in 2 countries.
Trial summary
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology
- What is being tested?
- AGS-16C3F
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- 9 sitesin 2 countries
- Study dates
- 18 Jul 2012to 21 Feb 2017
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Dose determination cohorts: Histologically confirmed diagnosis of metastatic RCC of either clear cell or non-clear histology.
- Tumors with clear cell histology: subject must have progressed after at least one anti-vascular endothelial growth factor receptor (anti-VEGFR) therapy
- Tumors with non-clear cell histology must be ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3) positive at pre-screening. This sub-group does not have any prior therapy requirement.
- Dose expansion cohorts: Histologically confirmed diagnosis of metastatic RCC of either clear cell or papillary histology
- Tumors with clear cell histology: subject must have progressed after at least one anti-VEGFR therapy
- Tumors with papillary histology: includes unclassified histology with papillary features and must be ENPP3 positive at pre-screening. This sub-group does not have any prior therapy requirement.
Show all 19Show fewer
- Measurable disease according to Response Criteria for Solid Tumors (RECIST Version 1.1)
- Eastern Cooperative Group (ECOG) performance status of 0-1
- Hematologic function, as follows:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count ≥ 100 x 109/L
- Hemoglobin ≥ 9 g/dL (transfusions are allowed)
- Renal function, as follows:
- creatinine ≤ 1.5 x upper limit of normal (ULN), or calculated glomerular filtration rate (GFR) > 50 mL/min if creatinine > 1.5x ULN
- Hepatic function, as follows:
- Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN or ≤ 5x ULN if known liver metastases
- Total bilirubin ≤1.5 x ULN
- International normalized ratio (INR) < 1.3 (or ≤ 3.0 if on therapeutic anticoagulation)
- Women and men of childbearing potential must be advised and agree to practice effective methods of contraception during the course of the study and for 4 weeks after the last AGS-16C3F infusion administration
Who cannot join
- Current uncontrolled central nervous system (CNS) metastasis or malignant brain tumors
- Use of any investigational drug (including marketed drugs not approved for this indication) within 4 weeks prior to screening. No time limit applies to the use of marketed drugs approved for this indication provided that the subject has progressed on the treatment and all toxicities attributable to the drug have resolved or returned to baseline
- Known sensitivity to any of the ingredients of the investigational product AGS-16C3F
- History of thromboembolic events and bleeding disorders ≤3 months (e.g., (deep vein thrombosis) DVT or pulmonary embolism (PE))
- Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 12 months of study enrollment, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by outpatient medication.
- Major surgery within 4 weeks of study enrollment
Show all 10Show fewer
- Women who are pregnant (confirmed by positive pregnancy test) or lactating
- Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B surface antigen.
- Active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of screening.
- History of eye surgery within 6 months, presence of cataracts or other ocular disorders significantly affecting vision
Trial locations and contacts
9 sites in 2 countries.
9 sites in 2 countries
United States5 sites
Site US00005 University of Michigan Medical Center
Ann Arbor, Michigan, 48109
Site US00004 Roswell Park Cancer Institute
Buffalo, New York, 14263
Site US00003 Karmanos Cancer Institute
Detroit, Michigan, 48201
Site US00002 Memorial Sloan-Kettering Cancer Center
New York, New York, 10065
Site US00001 Seattle Cancer Care Alliance
Seattle, Washington, 98109
Canada4 sites
Site CA00006 Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Site CA00009 London Health Sciences Centre
London, Ontario, N6A 4L6
Site CA00007 Jewish General Hospital
Montreal, Quebec, H3T 1E2
Site CA00008 British Columbia Cancer Agency
Vancouver, British Columbia, V5Z 4E6
About this study
Official title: A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).
Read the detailed description
The study has two components. The first aims to establish a safe dose for AGS-16C3F. Once identified, the safety and effectiveness will be tested in additional subjects with either clear cell or papillary histology in expanded cohorts.
- Conditions
- Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology
- Being tested
- AGS-16C3F
- Keywords
- Renal Cell Carcinoma, AGS-16C3F, Pharmacokinetics of AGS-16C3F
- Medical subject headings
- Carcinoma, Renal Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AGS-16C3FDrug
intravenous (IV) infusion
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1 AGS-16C3F highest dose | Experimental | Renal Cell Carcinoma subjects with clear and non-clear histology Receives: Drug: AGS-16C3F |
| Cohort 0 AGS-16C3F higher dose | Experimental | Renal Cell Carcinoma subjects with clear and non-clear histology Receives: Drug: AGS-16C3F |
| Cohort (-1) AGS-16C3F high dose | Experimental | Renal Cell Carcinoma subjects with clear and non-clear histology Receives: Drug: AGS-16C3F |
| Cohort (-2) AGS-16C3F middle dose | Experimental | Renal Cell Carcinoma subjects with clear and non-clear histology Receives: Drug: AGS-16C3F |
| Cohort (-3) AGS-16C3F low dose | Experimental | Renal Cell Carcinoma subjects with clear and non-clear histology Receives: Drug: AGS-16C3F |
| Cohort (-4) AGS-16C3F lowest dose | Experimental | Renal Cell Carcinoma subjects with clear and non-clear histology Receives: Drug: AGS-16C3F |
| AGS-16C3F in RCC Subjects with Clear Cell Histology | Experimental | Expansion Cohort Receives: Drug: AGS-16C3F |
| AGS-16C3F in RCC Subjects with Papillary Histology | Experimental | Expansion Cohort Receives: Drug: AGS-16C3F |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Adverse Events
Measured: 24 months
Secondary outcomes (5)
Pharmacokinetic profile for total antibody (TAb), antibody drug conjugate (ADC), and monomethyl auristatin F (MMAF): Ceoi or Cmax, Ctrough, Tmax, AUCτ, t1/2, CL, and Vss
Concentration at end of infusion (Ceoi) or maximum observed concentrations (Cmax), Trough concentration (Ctrough), time to maximum concentration (Tmax), partial area under the serum concentration-time curve (AUCτ), terminal or apparent half-life (t1/2), systemic clearance (CL), and volume of distribution at steady state (Vss)
Measured: Days 1, 2, 3, 4, 8, 15, 22, 43, 64, 65, 66, 67, 71, 78, and 92
Incidence of antidrug antibody formation to human native antibody (AGS-16C) and antibody drug conjugate (AGS-16C3F)
Measured: 24 months
Tumor response: objective response rate
Determined from the subjects' best response and will include complete response (CR) and partial response (PR)
Measured: 24 months
Tumor response: disease control rate
Determined from the subjects' best response will include complete response (CR) partial response (PR), and stable disease (SD)
Measured: 24 months
Tumor response: Changes in bone scans
Measured: Baseline, Week 13 and every 12 weeks thereafter
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2012 (estimated)
- Study start18 Jul 2012
- Primary completion21 Feb 2017
- Study completion21 Feb 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Carcinoma, Renal CellStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Agensys, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Director, Study director, Agensys, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01672775
- Sponsor's protocol ID
- AGS-16C3F-12-2
- Status last verified
- Oct 2024
- First submitted
- 22 Aug 2012
- Last updated
- 1 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No: Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Study at a glance
From the registry record, last updated by the sponsor on 1 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
- ClinicalTrials.gov ID
- NCT01672775
- Acronym / sponsor ID
- AGS-16C3F-12-2
- Conditions
- Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology
- Keywords
- Renal Cell Carcinoma, AGS-16C3F, Pharmacokinetics of AGS-16C3F
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Agensys, Inc.Industry (pharma, biotech, devices)
- Study start
- 18 Jul 2012 (actual)
- Primary completion
- 21 Feb 2017 (actual)
- Study completion
- 21 Feb 2017 (actual)
- First posted
- 27 Aug 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).
Detailed description
The study has two components. The first aims to establish a safe dose for AGS-16C3F. Once identified, the safety and effectiveness will be tested in additional subjects with either clear cell or papillary histology in expanded cohorts.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 8
| Arm | Type | Receives |
|---|---|---|
| Cohort 1 AGS-16C3F highest dose | Experimental | Drug: AGS-16C3FRenal Cell Carcinoma subjects with clear and non-clear histology |
| Cohort 0 AGS-16C3F higher dose | Experimental | Drug: AGS-16C3FRenal Cell Carcinoma subjects with clear and non-clear histology |
| Cohort (-1) AGS-16C3F high dose | Experimental | Drug: AGS-16C3FRenal Cell Carcinoma subjects with clear and non-clear histology |
| Cohort (-2) AGS-16C3F middle dose | Experimental | Drug: AGS-16C3FRenal Cell Carcinoma subjects with clear and non-clear histology |
| Cohort (-3) AGS-16C3F low dose | Experimental | Drug: AGS-16C3FRenal Cell Carcinoma subjects with clear and non-clear histology |
| Cohort (-4) AGS-16C3F lowest dose | Experimental | Drug: AGS-16C3FRenal Cell Carcinoma subjects with clear and non-clear histology |
| AGS-16C3F in RCC Subjects with Clear Cell Histology | Experimental | Drug: AGS-16C3FExpansion Cohort |
| AGS-16C3F in RCC Subjects with Papillary Histology | Experimental | Drug: AGS-16C3FExpansion Cohort |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (19 listed)
- Dose determination cohorts: Histologically confirmed diagnosis of metastatic RCC of either clear cell or non-clear histology.
- Dose expansion cohorts: Histologically confirmed diagnosis of metastatic RCC of either clear cell or papillary histology
- Measurable disease according to Response Criteria for Solid Tumors (RECIST Version 1.1)
- Eastern Cooperative Group (ECOG) performance status of 0-1
- Hematologic function, as follows:
Key exclusion criteria (10 listed)
- Current uncontrolled central nervous system (CNS) metastasis or malignant brain tumors
- Use of any investigational drug (including marketed drugs not approved for this indication) within 4 weeks prior to screening. No time limit applies to the use of marketed drugs approved for this indication provided that the subject has progressed on the treatment and all toxicities attributable to the drug have resolved or returned to baseline
- Known sensitivity to any of the ingredients of the investigational product AGS-16C3F
- History of thromboembolic events and bleeding disorders ≤3 months (e.g., (deep vein thrombosis) DVT or pulmonary embolism (PE))
- Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 12 months of study enrollment, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by outpatient medication.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AGS-16C3Fintravenous (IV) infusion | Drug | AGS-16C3F in RCC Subjects with Clear Cell Histology, AGS-16C3F in RCC Subjects with Papillary Histology, Cohort (-1) AGS-16C3F high dose, Cohort (-2) AGS-16C3F middle dose, Cohort (-3) AGS-16C3F low dose, Cohort (-4) AGS-16C3F lowest dose, Cohort 0 AGS-16C3F higher dose, Cohort 1 AGS-16C3F highest dose |
Primary outcome
Incidence of Adverse Events
Time frame: 24 months
5 secondary outcomes
Pharmacokinetic profile for total antibody (TAb), antibody drug conjugate (ADC), and monomethyl auristatin F (MMAF): Ceoi or Cmax, Ctrough, Tmax, AUCτ, t1/2, CL, and Vss
Time frame: Days 1, 2, 3, 4, 8, 15, 22, 43, 64, 65, 66, 67, 71, 78, and 92
Incidence of antidrug antibody formation to human native antibody (AGS-16C) and antibody drug conjugate (AGS-16C3F)
Time frame: 24 months
Tumor response: objective response rate
Time frame: 24 months
Tumor response: disease control rate
Time frame: 24 months
Tumor response: Changes in bone scans
Time frame: Baseline, Week 13 and every 12 weeks thereafter
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Nov 2024.
- Individual participant dataSharing planned: No. Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Related trials for Carcinoma, Renal Cell
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Not yet recruitingPhase 2
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma
Not yet recruitingPhase 2
Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma
Localized Clear Cell Renal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director study director
Agensys, Inc.
9 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing AGS-16C3F in people with Carcinoma, Renal Cell and Renal Cell Carcinoma of Papillary Histology, run by Agensys, Inc. at 9 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Adverse Events (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2024.